(Q51334647)

English

Tyrphostin AG490 agent modestly but significantly prevents onset of type 1 in NOD mouse; implication of immunologic and metabolic effects of a Jak-Stat pathway inhibitor.

scientific article published on 4 June 2012

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22661285

Tyrphostin AG490 agent modestly but significantly prevents onset of type 1 in NOD mouse; implication of immunologic and metabolic effects of a Jak-Stat pathway inhibitor. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22661285

Clive Wasserfall

3

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22661285

author name string

Abdoreza Davoodi-Semiromi

1

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22661285

Azadeh Hassanzadeh

2

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22661285

Andrew Droney

4

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22661285

Mark Atkinson

5

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22661285

publication date

4 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22661285

Journal of Clinical Immunology

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22661285

32

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22661285

5

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22661285

1038-1047

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22661285

Prevention of autoimmune diabetes in NOD mice by troglitazone is associated with modulation of ICAM-1 expression on pancreatic islet cells and IFN-γ expression in splenic T cells

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Impact of common variants of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 on the risk of type 2 diabetes in 5,164 Indians.

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Tyrphostin AG490, a tyrosine kinase inhibitor, blocks actively induced experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

A mutant Stat5b with weaker DNA binding affinity defines a key defective pathway in nonobese diabetic mice

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Human SGBS cells - a unique tool for studies of human fat cell biology

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Tyrphostins as potential therapeutic agents for acute kidney injury

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Prevention of acute lung allograft rejection in rat by the janus kinase 3 inhibitor, tyrphostin AG490.

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

No association of multiple type 2 diabetes loci with type 1 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Ciliary neurotrophic factor (CNTF) signals through STAT3-SOCS3 pathway and protects rat pancreatic islets from cytokine-induced apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Obesity associated with a mutation in a genetic regulator of adipocyte differentiation

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Small molecule tyrosine kinase inhibitors for the treatment of intestinal inflammation

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Characterization of a human preadipocyte cell strain with high capacity for adipose differentiation

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Lack of association of type 2 diabetes susceptibility genotypes and body weight on the development of islet autoimmunity and type 1 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Differential transcriptional expression of PPARalpha, PPARgamma1, and PPARgamma2 in the peritoneal macrophages and T-cell subsets of non-obese diabetic mice

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Involvement of JAK2 and Src kinase tyrosine phosphorylation in human growth hormone-stimulated increases in cytosolic free Ca2+ and insulin secretion

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9707-Y

21 January 2018

Targeting tyrosine kinases in cancer: the second wave

1 reference

https://pubmed.ncbi.nlm.nih.gov/22661285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of experimental autoimmune encephalomyelitis by a tyrosine kinase inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/22661285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22661285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correspondence regarding "Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats".

1 reference

https://pubmed.ncbi.nlm.nih.gov/22661285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Truncated pStat5B is associated with the Idd4 locus in NOD mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22661285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy with AG-490 and interleukin 12 achieves greater antitumor effects than either agent alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/22661285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/22661285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse

1 reference

https://pubmed.ncbi.nlm.nih.gov/22661285

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10875-012-9707-Y

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22661285

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 April 2018

http://europepmc.org/abstract/MED/22661285

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51334647&oldid=2210817722"